AstraZeneca and GSK Both Deepen China Ties Through Sino Biopharm in One Day as Vertex Buys Crinetics for ~$10B and Vera's Atacicept Wins FDA Approval

Sino Biopharmaceutical drove the week from both sides of the US-China axis. On July 8, its subsidiary Chia Tai Tianqing out-licensed the inhaled PDE3/4 inhibitor TQC3721 to AstraZeneca for all territories outside China (with global rights for certain future programs), taking $200M upfront, up to $1.9B in milestones (up to about $2.1B total) and tiered double-digit royalties. TQC3721 has generated Phase IIb COPD data and is in Phase III (nebulized) and Phase II (dry powder inhaler) development in China; AstraZeneca positions it as a challenger to Merck's Ohtuvayre (ensifentrine), the marketed PDE3/4 inhibitor. It is another example of a China-originated respiratory asset moving into an MNC's global pipeline on upfront-light, milestone-heavy terms.

The same day, GSK moved in the opposite direction, expanding an alliance first signed in May 2026 to grant Chia Tai Tianqing the mainland-China commercialization rights to two respiratory blockbusters, Trelegy Ellipta and Anoro Ellipta; Sino Biopharm will handle importation, distribution, hospital access and promotion. The pairing is a clean illustration of the two-way trade BioLink tracks: Chinese innovation flowing out to Western buyers while Western commercial assets flow in through Chinese commercial partners. On M&A, Vertex agreed to acquire Crinetics Pharmaceuticals for $85.00 per share (about $10.0B equity value, about $8.8B net of cash) - an endocrinology diversification anchored by the acromegaly drug Palsonify (paltusotine) and the Phase 3 CAH candidate atumelnant. That transaction was announced July 6, one day before this window opened and not covered in the prior issue, and is tabled below with an explicit boundary flag. As always, BD professionals should anchor to near-term cash and de-risking: the AZ-Sino license again paired a modest upfront with a billion-dollar-plus milestone tail.

July 7, 2026 - FDA Grants Accelerated Approval to Vera Therapeutics' Trutakna (atacicept) in IgA Nephropathy

The FDA granted accelerated approval to TRUTAKNA (atacicept; Vera Therapeutics) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of disease progression - the first and only therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL). It is a 150 mg once-weekly subcutaneous self-administered autoinjector. In a prespecified interim analysis of the ORIGIN Phase 3 trial, atacicept achieved a 46% reduction from baseline in proteinuria and a 42% reduction versus placebo at week 36. The accelerated approval is based on proteinuria reduction; a long-term benefit on kidney-function decline has not yet been established.

BD Implication: A differentiated dual-cytokine (BAFF/APRIL) mechanism reaching approval in an increasingly crowded IgAN field confirms that mechanism plus route/dosing convenience drives positioning in autoimmune renal disease - directly relevant to the ANCA-associated vasculitis, anemia-of-CKD, and cardiovascular/kidney buyer mandates on the Opportunity Board. Issue 13 flagged this July 7 decision as pending; the outcome is now reported.

July 9, 2026 - FDA Approves Subcutaneous Sarclisa Escena (isatuximab-irfc) Across Multiple Myeloma Indications

The FDA approved a subcutaneous formulation of the anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa Escena) across its multiple myeloma indications, administered via the CirCLIQ On-Body Delivery System or by syringe. Approval was supported by the IRAKLIA Phase 3 non-inferiority study comparing on-body-injector subcutaneous isatuximab to weight-based IV, both with pomalidomide and dexamethasone in relapsed/refractory myeloma, with comparable activity (overall response rate 71.1% subcutaneous versus 70.5% IV).

BD Implication: Route-of-administration reformulation with an on-body device is a lifecycle and competitive-differentiation lever, not just a convenience upgrade - a benchmark for China-origin anti-CD38 and broader myeloma programs weighing how to compete on delivery as well as efficacy in Western markets.

July 13, 2026 - Q32 Bio Reports Positive 36-Week Phase 2a Data for Bempikibart (IL-7Ralpha) in Alopecia Areata

Q32 Bio reported positive 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial of bempikibart, an IL-7 receptor alpha (IL-7Ralpha) antibody, in 33 patients with severe or very severe alopecia areata, including patients previously treated with JAK inhibitors. Patients showed a mean 35.3% reduction in SALT score (mITT), with 40.0% achieving SALT-20 and 44.0% reaching SALT30 and SALT50 at week 36, plus early signs of durable off-drug responses including one complete regrowth. The antibody was generally well tolerated, with no treatment-related serious or Grade 3+ adverse events; shares rose more than 80% on the day.

BD Implication: A novel upstream immunology mechanism (IL-7Ralpha) showing durable, potentially off-drug responses in a JAK-inhibitor-experienced autoimmune population is exactly the kind of differentiated immunology asset Western buyers and funds are chasing - a reference point for China-origin immunology programs positioning against the crowded JAK field.

Calendar and validation notes: A Merck / Verona Pharma transaction resurfaced under a July 2026 date and is confirmed a July 2025 deal (completed October 2025); it is omitted. Sources conflicted on the Sarclisa Escena subcutaneous approval date (July 9 versus July 10); the FDA approval notice and named oncology outlets support July 9, used here.